Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 25:2:101842.
doi: 10.1016/j.gimo.2024.101842. eCollection 2024.

A multitiered analysis platform for genome sequencing: Design and initial findings of the Australian Genomics Cardiovascular Disorders Flagship

Collaborators, Affiliations

A multitiered analysis platform for genome sequencing: Design and initial findings of the Australian Genomics Cardiovascular Disorders Flagship

Rachel Austin et al. Genet Med Open. .

Abstract

Purpose: The Australian Genomics Cardiovascular Disorders Flagship was a national multidisciplinary collaboration. It aimed to investigate the feasibility of genome sequencing (GS) and functional genomics to resolve variants of uncertain significance (VUS) in the clinical management of patients and families with cardiomyopathies, primary arrhythmias, and congenital heart disease (CHD).

Methods: Between April 2019 and December 2021, 600 probands meeting cardiovascular disorder criteria from 17 cardiology and genetics clinics across Australia were enrolled in the Flagship and underwent GS. The Flagship adopted a tiered approach to GS analysis. Tier 1 analysis assessed genes with established clinical validity for each cardiovascular condition. Tier 2 analysis assessed lesser-evidenced research-based genes. Tier 3 analysis assessed the functional impact of VUS that remained after tier 1 and tier 2 analysis.

Results: Overall, a pathogenic or likely pathogenic variant was identified in 41% of participants with a cardiomyopathy, 40% with an arrhythmia syndrome, and 15% with a familial CHD/CHD+Extra Cardiac Anomalies. A VUS outcome ranged from 13% for arrhythmias to 34% for CHD/CHD+Extra Cardiac Anomalies participants. Tier 2 research analysis identified a likely pathogenic/pathogenic variant for a further 15 participants and a VUS for an additional 15 participants.

Conclusion: The Flagship successfully facilitated a model of care that harnesses clinical GS and functional genomics for the resolution of VUS in the clinical setting. This valuable data set can be used to inform clinical practice and facilitate research into the future.

Keywords: Australian Genomics; Cardiovascular genetic disorders; Genome sequencing; Specialized multidisciplinary care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schema of participant recruitment, approach to clinical and research sequencing, variant curation, and the resolution of VUS. Stages of feedback to participants are also illustrated.
Figure 2
Figure 2
Number of participants recruited from each Australian State and Territory.
Figure 3
Figure 3
Summary of tier 1 clinically curated diagnostic rate (%) for the 3 clinical diagnosis categories (n = 600).

References

    1. Girolami F., Frisso G., Benelli M., et al. Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. J Cardiovasc Med (Hagerstown) 2018;19(1):1–11. doi: 10.2459/JCM.0000000000000589. - DOI - PMC - PubMed
    1. Isbister J., Semsarian C. Cardiovascular genomics and sudden cardiac death in the young. Aust J Gen Pract. 2019;48(3):90–95. doi: 10.31128/AJGP-09-18-4715. - DOI - PubMed
    1. Pierpont M.E., Brueckner M., Chung W.K., et al. Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association. Circulation. 2018;138(21):e653–e711. doi: 10.1161/CIR.0000000000000606. - DOI - PMC - PubMed
    1. Giudicessi J.R., Ackerman M.J., Fatkin D., Kovacic J.C. Precision medicine approaches to cardiac arrhythmias: JACC focus seminar 4/5. J Am Coll Cardiol. 2021;77(20):2573–2591. doi: 10.1016/j.jacc.2021.03.325. - DOI - PubMed
    1. Fatkin D., Calkins H., Elliott P., James C.A., Peters S., Kovacic J.C. Contemporary and future approaches to precision medicine in inherited cardiomyopathies: JACC focus seminar 3/5. J Am Coll Cardiol. 2021;77(20):2551–2572. doi: 10.1016/j.jacc.2020.12.072. - DOI - PubMed

LinkOut - more resources